Tristan Bolmont, Ph.D.
Stemedica International’s Chief Scientist
Dr. Tristan Bolmont joined Stemedica International in October 2013 after a two-year collaboration as a principal investigator on an Alzheimer imaging (AIM) and stem cell therapy academic project funded by the Swiss Commission for Technology and Innovation (CTI). As Stemedica International’s chief scientist, he leads the team in preparing scientific research data and supporting clinical trials that apply stem cells and factors to treat Alzheimer’s disease, vascular dementia and related disorders. Before joining Stemedica International, he held several academic positions, including research scientist at Switzerland’s École Polytechnique Fédérale de Lausanne (EPFL) Optique Biomédicale, as well as its Molecular and Cellular Biology of Alzheimer’s Disease Laboratories. He also served as a post-doctoral researcher for the University of Tübingen’s Hertie Institute for Clinical Brain Research in Germany and was a doctoral researcher at the University of Basel’s Institute of Pathology. Before earning his doctorate, he was a research assistant at University of Strasbourg’s Neurosciences Comportementales et Cognitives Laboratory in France. Dr. Bolmont has contributed to more than 15 papers in high-profile, peer-reviewed journals like Science and PNAS, and has applied for several international patents. He earned his Ph.D. in neurobiology from the University of Basel, Switzerland, and his M.Sc. in neuroscience and B.A. in cognitive and experimental psychology from the University of Strasbourg, France.